During Radiation Treatment For Prostate Cancer The Antioxidant Beta-Carotene Found To Be Safe
6/05/2012
Despite past safety concerns, the antioxidant supplement beta-carotene, is safe to use during radiation therapy treatments for prostate cancer and does not increase the risk of prostate cancer death or metastases, according to a study in the International Journal of Radiation Oncology-Biology-Physics, the official scientific journal of the American Society for Radiation Oncology (ASTRO)...
Detailing Protein Pathways May Provide Clues In Leukemia Research
6/05/2012
Scientists at Rice University and the University of Texas MD Anderson Cancer Center have successfully profiled protein pathways found to be distinctive to leukemia patients with particular variants of the disease. Their research involved the creation of a new computational approach to identifying complex networks in protein signaling...
Novel Combination Activates Two Key Genes Involved In Lung Cancer
6/05/2012
A team of researchers led by Dr. Goutham Narla at Case Western Reserve University School of Medicine in collaboration with scientists at Mount Sinai School of Medicine in New York, have discovered a previously unrecognized signaling network disrupted in lung cancer that can be turned back on by a novel combination of two previously approved FDA drugs...
Notch Network Findings Further The Development Of Cancer, Heart Disease Therapeutics
6/05/2012
By using laser microbeam technology called optical tweezers, UC Irvine and UCLA researchers have uncovered fundamental properties of a key molecular signaling system involved with development, cancer and cardiovascular disease...
News From The Journal Of Clinical Investigation
6/05/2012
METABOLISM Improving obesity-induced insulin sensitivity In recent years, a growing body of evidence has linked inflammation to the development of insulin resistance. In insulin resistance, the hormone insulin is less effective in promoting glucose uptake from the bloodstream into other tissues...
Overcoming Drug Resistance In Cancer
6/05/2012
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed resistance to these drugs and are therefore no longer responsive to drug treatment...
Clinical Trial Design Supports Original Accelerated Approval Of Sunitinib For GIST
6/05/2012
Patients benefitted from an important design element in the pivotal phase III clinical trial that led to Food and Drug Administration and worldwide regulatory approval of sunitinib for the treatment of gastrointestinal stromal tumors resistant to the only other available therapy, according to a study in /iClinical Cancer Research, a journal of the American Association for Cancer Research...
Study Of 2 Million Patients Looks At Vena Cava Filters, Outlines Embolism Treatments
6/05/2012
A filter used to block clots from passing from the veins in the legs to the arteries of the lung does not improve mortality rates for most patients suffering a pulmonary embolism. However, if a patient is unstable - in shock or requires a ventilator - filters can save lives...
Genentech's Trastuzumab Emtansine (T-DM1) Reduces The Risk Of Cancer Worsening
6/04/2012
Roche announced today that it's division, known as Genentech, has produced positive results in a phase three EMILIA study of a drug called trastuzumab emtansine (T-DM1). Genentech says that the drug met the endpoint target for the trial, showing marked improvement for women with HER2-positive metastatic breast cancer...
Dabrafenib And Trametinib For Metastatic Melanoma Meet Primary Endpoints In Phase III Studies
6/04/2012
Phase III human trials of single agent therapy using dabrafenib and trametinib for patients with BRAF V600 mutation positive metastatic melanoma met their primary endpoints, GSK (GlaxoSmithKline) reported at the Annual Meeting of ASCo (American Society of Clinical Oncology), Chicago, Illinois, today. The trial results were also published today in NEJM (New England Journal of Medicine)...